Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Finished Goods (2021)

VYNE Therapeutics' Finished Goods history spans 1 years, with the latest figure at $4.0 million for Q4 2021.

  • For Q4 2021, Finished Goods changed N/A year-over-year to $4.0 million; the TTM value through Dec 2021 reached $4.0 million, changed N/A, while the annual FY2021 figure was $4.0 million, N/A changed from the prior year.
  • Finished Goods reached $4.0 million in Q4 2021 per VYNE's latest filing.
  • In the past five years, Finished Goods ranged from a high of $4.0 million in Q4 2021 to a low of $4.0 million in Q4 2021.